Clinical Outcome of Salmon Calcitonin Nasal Spray Treatment in Postmenopausal Women after Total Hip Arthroplasty

Abstract

Objective: The increasing rate of hip fractures is giving rise to a number of socio-economic problems for the aging community. In addition to being unable to resume their previous living habits, many patients fail to achieve full functional recovery after the fractures. Total hip arthroplasty (THA) is a successful operation for the majority of patients with all forms of hip fractures, being performed increasingly often throughout the world. Revision rates for THA range up to 20% per year. Aseptic loosening is the reason for 75% of the revisions. An additional problem post-THA is the rate of heterotopic soft tissue calcification after THA, resulting in severely impaired function, pain, and a reduced range of hip movement. Subjects: In an open study, 37 women who had undergone cementless THA after accidental hip fractures were treated twice daily with 200 IU of salmon calcitonin nasal spray for 12 months. Simultaneously the patients received one bag of 1,000 mg calcium plus 880 IU vitamin D daily throughout the treatment period of 1 year. A parallel group of 38 women with a similar clinical status in terms of hip fractures and cementless THA were treated with only one bag of 1,000 mg calcium plus 880 IU vitamin D daily through the treatment period. Results: The results of this 12-month clinical trial show that 200 IU of salmon calcitonin nasal spray per day significantly improves the clinical outcome of postmenopausal elderly women following THA. Treatment with a salmon calcitonin nasal spray significantly reduces bone turnover, loss of bone density, and pain. The functional status of the patients was improved and the risk of falling reduced by rehabilitation during the observation period of 12 months. Additionally, calcitonin promoted the repair of hip fractures and was associated with a significantly lesser rate of refractures as well as periprosthetic ossifications. Conclusion: The increasing revision rate for THA during the first year and the patient’s problem of resuming their previous living habits are the main foci of our study. Calcitonin nasal spray seems to cause few side effects. The additive treatment appears to improve the clinical outcome of THA in elderly postmenopausal women.

The plant decapeptide OSIP108 prevents copper-induced apoptosis in yeast and human cells

“…However an array of approaches currently exists to improve the pharmacological properties of peptides [56, 57]. For instance, oral insulin formulations already show promising results as treatment of diabetes type 1 [58] and nasal administrations of peptides such as the polypeptide hormone calcitonin [59] have been successfully tested in clinical trials. Hence, further preclinical and clinical development of OSIP108 as a novel therapy for diseases related to excessive apoptosis such as WD or some neurodegenerative diseases, will require considerable efforts in the development of adequate OSIP108 formulations.…”

Periprosthetic Fractures: Epidemiology and Future Projections

“…23 Calcitonin has also been examined and may be of benefit. 24 Parathyroid hormone is postulated to be of benefit as a result of its effects on bone mass, although this has not been proven. 25 …”

Apoptotic pathways of macrophages within osteolytic interface membrane in periprosthestic osteolysis after total hip replacement

“…There is recent evidence that bisphosphonates (BPs), known to induce macrophage apoptosis, are of potential therapeutic use in the treatment of experimental osteolysis . Rogers et al showed that apoptosis could be induced in the J774 and RAW264 macrophage cell lines by treatment with pamidronate, alendronate, ibandronate, and clodronate.…”